参考文献
[1] AIDSinfo. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. December 1, 2007. Accessed October 2016. Available at: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/7/hla-b--5701-screening
[2] American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA). When and in whom to initiate HCV therapy. July 2016. In: HCV guidance: recommendations for testing, managing, and treating hepatitis C. Accessed October 2016. Available at: http://www.hcvguidelines.org/full-report/when-and-whom-initiate-hcv-therapy
[3] American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA). Monitoring patients who are starting hepatitis C treatment, are on treatment, or have completed therapy. September 2016. In: HCV guidance: recommendations for testing, managing, and treating hepatitis C. Accessed October 2016. Available at: http://www.hcvguidelines.org/full-report/monitoring-patients-who-are-starting-hepatitis-c-treatment-are-treatment-or-have
[4] American Society of Addiction Medicine (ASAM). Principles for Outcome Evaluation in the Treatment of Substance-Related Disorders: a Joint AMBHA-ASAM Statement. 2001. Accessed December 2016. Available at: http://www.asam.org/docs/default-source/public-policy-statements/1outcome-evaluation-1-012.pdf?sfvrsn=0
[5] Buffler PA, Ginevan ME, Mandel JS, Watkins DK. The Air Force health study: an epidemiologic retrospective. Ann Epidemiol. 2011 Sep;21(9):673–87. doi: 10.1016/j.annepidem.2011.02.001. PubMed PMID: 21441038.
[6] Committee on the Management of the Air Force Health Study Data and Specimens—Report to Congress; Board on the Health of Select Populations; Institute of Medicine. The Air Force Health Study Assets Research Program. Washington (DC): National Academies Press (US); 2015 Apr 9. Available from: https://www.ncbi.nlm.nih.gov/books/NBK286027/ . doi: 10.17226/20219.
[7] Committee to Review the Health Effects in Vietnam Veterans of Exposure to Herbicides (Tenth Biennial Update); Board on the Health of Select Populations; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine. Veterans and Agent Orange: Update 2014. Washington (DC): National Academies Press (US); 2016 Mar 29. Available from: https://www.ncbi.nlm.nih.gov/books/NBK356074/ . doi: 10.17226/21845.
[8] Freedland SJ, Moul JW. Prostate specific antigen recurrence after definitive therapy. J Urol. 2007 Jun;177(6):1985–91. doi: 10.1016/j.juro.2007.01.137. PubMed PMID: 17509277.
[9] Gundogdu F, Soylu F, Erkan L, Tatli O, Mavi S, Yavuzcan A. The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors). Arch Gynecol Obstet. 2011 Jun;283(6):1397–402. doi: 10.1007/s00404-010-1589-8. PubMed PMID: 20645105.
[10] Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis. 2002 Jun;23(6):907–922. doi: 10.1093/carcin/23.6.907. PubMed PMID: 12082012.
[11] Hecht SS, Carmella SG, Edmonds A, Murphy SE, Stepanov I, Luo X, Hatsukami DK. Exposure to nicotine and a tobacco-specific carcinogen increase with duration of use of smokeless tobacco. Tob Control. 2008 Apr;17(2):128–31. doi: 10.1136/tc.2007.023242. doiPMCID: PMC3889131. PubMed PMID: 18375734.
[12] Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH; American College of Chest Physicians. Chest. 2012 Feb;141(2 Suppl):e152S–84S. 10.1378/chest.11-2295. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. doi. PubMed PMID: 22315259.
[13] IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Smokeless Tobacco and Some Tobacco-specific N-Nitrosamines. Lyon (FR): International Agency for Research on Cancer; 2007. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 89.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK326497/
[14] Kheyfets VO, Dunning J, Truong U, Ivy DD, Hunter KA, Shandas R. Assessment of N-terminal prohormone B-type natriuretic peptide as a measure of vascular and ventricular function in pediatric pulmonary arterial hypertension. Pulm Circ. 2015 Dec;5(4):658–66. doi: 10.1086/683697. PubMed PMID: 26697173.
[15] Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ 3rd. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002 Feb 21;346(8):564–9. doi: 10.1056/NEJMoa01133202. PubMed PMID: 11856795.
[16] Mallery SR, Tong M, Michaels GC, Kiyani AR, Hecht SS. Clinical and biochemical studies support smokeless tobacco's carcinogenic potential in the human oral cavity. Cancer Prev Res (Phila). 2014 Jan;7(1):23–32. doi: 10.1158/1940-6207.CAPR-13-0262. Epub 2013 Nov 21PMCID: PMC3892990. PubMed PMID: 24265177.
[17] Papageorghiou A, Ohuma E, Gravett M, Hirst J, Silveira M, Lambert A, Carvalho M, Jaffer Y, Altman D, Noble J, Bertino E, Purwar M, Pang R, Ismail L, Victora C, Bhutta Z, Kennedy S, Villar J. International standards for symphysis-fundal height based on serial measurements from the Fetal Growth Longitudinal Study of the INTERGROWTH-21st Project: prospective cohort study in eight countries. BMJ. 2016 Oct;355:i5662. doi: 10.1136/bmj.i5662. PubMed PMID: 27821614.
[18] Park SL, Carmella SG, Ming X, Vielguth E, Stram DO, Le Marchand L, Hecht SS. Variation in levels of the lung carcinogen NNAL and its glucuronides in the urine of cigarette smokers from five ethnic groups with differing risks for lung cancer. Cancer Epidemiol Biomarkers Prev. 2015 Mar;24(3):561–9. doi: 10.1158/1055-9965.EPI-14-1054. PubMed PMID: 25542827.
[19] Robinson JN, Fox KA, Jackson WG, Ketchum NS, Pavuk M, Grubbs W. Air Force Health Study – An Overview. Organohalogen Compd. 2006;68:752–5. Accessed December 2016.
[20] Rustin GJ, Marples M, Nelstrop AE, Mahmoudi M, Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol. 2001 Oct 15;19(20):4054–7. doi: 10.1200/jco.2001.19.20.4054. PubMed PMID: 11600607.
[21] Sandler HM, Eisenberger MA. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy. J Urol. 2007;178:S20–S24. doi: 10.1016/j.juro.2007.04.034. PubMed PMID: 17644123.
[22] Schick SF, Blount BC, Jacob P. Rd, Saliba NA, Bernert JT, El Hellani A, Jatlow P, Pappas RS, Wang L, Foulds J, Ghosh A, Hecht SS, Gomez JC, Martin JR, Mesaros C, Srivastava S, St Helen G, Tarran R, Lorkiewicz PK, Blair IA, Kimmel HL, Doerschuk CM, Benowitz NL, Bhatnagar A. Biomarkers of exposure to new and emerging tobacco delivery products. Am J Physiol Lung Cell Mol Physiol. 2017 Sep 1;313(3):L425–L452. doi: 10.1152/ajplung.00343.2016. Epub 2017 May 18PMCID: PMC5626373. PubMed PMID: 28522563.
[23] ten Kate CA, Tibboel D, Kraemer US. B-type natriuretic peptide as a parameter for pulmonary hypertension in children. A systematic review. Eur J Pediatr. 2015 Oct;174(10):1267–75. doi: 10.1007/s00431-015-2619-0. PubMed PMID: 26298682.
[24] Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM; AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007 Jun;177(6):2106–31. doi: 10.1016/j.juro.2007.03.003. PubMed PMID: 17509297.
[25] Yalcin E, de la Monte S. Tobacco nitrosamines as culprits in disease: mechanisms reviewed. J Physiol Biochem. 2016 Mar;72(1):107–20. doi: 10.1007/s13105-016-0465-9. Epub 2016 Jan 14PMCID: PMC4868960. PubMed PMID: 26767836.
/3 
浙公网安备33010802005999号 
